New Annuloplasty Devices from MiCardia Approved
The Dynaplasty Annuloplasty Band DR and Annuloplasty Ring DR, both manufactured by MiCardia Corporation, were approved for marketing by the Food and Drug Administration. Patients with tricuspid valve regurgitation, congestive heart failure, and mitral valve regurgitation are eligible for treatment with this system, as reported by Medical News Today.
The MiCardia Dynaplasty technology is a reduced risk alternative for patients with mitral valve regurgitation who undergo intra-operative percutaneous or non-invasive mitral valve optimization. The rings are designed to adjust dynamically after surgical placement. The technology additionally supports changes to the size and shape of the rings, which can be viewed in real-time with echocardiography.
The rings are available in both rigid and semi-rigid shapes according to information provided by the organization. These can be used to treat patients with regurgitant valves from a variety of different underlying conditions.
One advantage of this technology compared to others is that the system optimizes repair outcomes intra-operatively. These are also adjusted long-term, supporting valve competency management across time.
Bands for annuloplasty are utilized to help remodel fibrous tissue at the base of valve. Rings, alternatively, are implanted in the same location to support the natural anatomy, as well as flexibility and motion of the valve.
September 12, 2008 Related topics: Product Approval & Certification, New Technology & Innovation, Quality, Safety, Errors, Cardiology